Douglass Given, MD, PhD
Doug is Managing Partner at Health2047 Capital Partners. He served as Health2047 Inc.’s Chief Executive from its founding in August of 2015 until January 2018. An experienced board member, Doug currently serves as a Director at Health2047 Inc. and board Chair at both Akiri Inc. and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR). He provides expertise in healthcare innovation, biotechnology, biopharmaceuticals, and specialty medical products.
Katie Given, MD, PhD
Dr. Katie Given Ligtenberg is a dermatology resident at Yale, after completing her internal medicine internship at the University of Chicago. She earned her MD, PhD, and MBA from the University of Chicago, with focus in the genetics, molecular and cell biology of select agents, biodefense, and vaccine microbiology translational research. She served as an Innovation Associate at Chicago’s Polsky Center for Entrepreneurship and Innovation, serving with the investment teams for faculty new business formation.
Annie Given, BS
Annie formerly served as Director of Finance for Noa Technologies in Berlin, Germany. Her expertise is in financial and operations management, particularly for startups. Prior to her 5 years in Berlin, she worked with Global BSN in San Francisco and was an investment banking analyst at Stifel in NYC, in the Financial Institutions Group. Annie received her BS in Economics and Mathematics from the University of Southern California.
Nick Leeper, MD
A tenured associate professor of surgery and medicine at Stanford University School of Medicine, Nick’s clinical focus is in vascular medicine and cardiovascular disease. He regularly publishes on related topics in the space, holds two RO1 grants and is an active innovator.
Randy Thompson, MD
Randy has practiced medicine with Saint Luke’s Cardiovascular Consultants since 1995. His academic history spans, Emory, Massachusetts General Hospital and Harvard Medical School, and The Mayo Clinic. He is member of the Board of Directors of the American Society of Nuclear Cardiology.
Ben is a founding officer of ALD Connect, a research consortium focused on the neuro-metabolic disease X-linked adrenoleukodystrophy (X-ALD). Currently, he serves as director of business development at Alta Devices, a solar energy startup in Sunnyvale, CA.
Karl, an engineer, is the managing director of Innovation Portfolio Partners, a Silicon Valley-based firm that helps CEOs and the top management of Fortune 500 companies find and develop new-to-the-world products and services. He is on the advisory boards of Johns Hopkins Bloomberg School of Public Health, the University of Toledo, and Enviroscent.
Cindy Fong-Leeper, JD
Currently an associate general counsel at Facebook, Cindy holds a JD degree from University of Chicago Law School. Prior to joining Facebook in 2011, she served as an associate at Latham & Watkins in San Francisco and Menlo Park for seven years.